Mirum Targets $500m Sales For Just-Approved Rare Liver Disorder Drug
FDA Green Light For Alagille Syndrome Therapy Livmarli
Regulators have approved Mirum's IBAT inhibitor as the first medication for a genetic disorder which affects up to 2,500 children in the US.
